Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
GOSS Gossamer Bio	$1.30 -4.4%	$1.15	$0.66 ▼ $1.55	$309.13M	1.85	1.37 million shs	1.25 million shs
OKYO OKYO Pharma	$2.42 -2.0%	$1.81	$0.81 ▼ $3.11	$83.58M	-0.27	147,798 shs	48,491 shs
OLMA Olema Pharmaceuticals	$4.56 -4.0%	$4.69	$2.86 ▼ $16.62	$325M	1.99	816,597 shs	859,417 shs
PRME Prime Medicine	$2.65 +9.5%	$1.54	$1.11 ▼ $6.75	$347.93M	1.55	1.48 million shs	2.65 million shs

The 10 Best AI Stocks to Own in 2025

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
GOSS Gossamer Bio	-4.41%	+0.78%	+16.07%	+11.11%	+38.40%
OKYO OKYO Pharma	-2.02%	+7.56%	+38.29%	+79.26%	+105.08%
OLMA Olema Pharmaceuticals	-4.00%	+11.22%	-11.46%	+10.95%	-58.77%
PRME Prime Medicine	+9.50%	+47.22%	+108.66%	+33.17%	-47.78%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
GOSS Gossamer Bio	3.6571 of 5 stars	3.5	1.0	4.7	2.0	1.7	0.0
OKYO OKYO Pharma	2.57 of 5 stars	3.5	3.0	0.0	3.3	1.7	0.0
OLMA Olema Pharmaceuticals	2.5875 of 5 stars	3.5	1.0	0.0	3.3	2.5	0.6
PRME Prime Medicine	3.907 of 5 stars	4.4	1.0	0.0	3.4	5.0	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
GOSS Gossamer Bio	3.00	Buy	$7.33	464.10% Upside
OKYO OKYO Pharma	3.00	Buy	$7.00	189.26% Upside
OLMA Olema Pharmaceuticals	3.00	Buy	$24.50	437.28% Upside
PRME Prime Medicine	2.75	Moderate Buy	$10.08	280.50% Upside

Current Analyst Ratings Breakdown

Latest OKYO, GOSS, PRME, and OLMA Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
5/27/2025	PRME Prime Medicine	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Neutral	$10.00 ➝ $1.50
5/20/2025	PRME Prime Medicine	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Market Outperform ➝ Market Outperform	$10.00 ➝ $6.00
5/20/2025	PRME Prime Medicine	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Buy ➝ Neutral
5/20/2025	PRME Prime Medicine	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Neutral
5/19/2025	PRME Prime Medicine	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$16.00 ➝ $12.00
5/16/2025	GOSS Gossamer Bio	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$7.00 ➝ $8.00
5/16/2025	GOSS Gossamer Bio	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform	$4.00 ➝ $4.00
5/14/2025	OLMA Olema Pharmaceuticals	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$20.00 ➝ $18.00
5/14/2025	OLMA Olema Pharmaceuticals	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$25.00 ➝ $22.00
5/5/2025	OKYO OKYO Pharma	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$7.00 ➝ $7.00
4/28/2025	OLMA Olema Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$30.00 ➝ $30.00

(Data available from 6/27/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
GOSS Gossamer Bio	$114.70M	2.58	N/A	N/A	$0.13 per share	10.00
OKYO OKYO Pharma	N/A	N/A	N/A	N/A	($0.20) per share	N/A
OLMA Olema Pharmaceuticals	N/A	N/A	N/A	N/A	$7.14 per share	N/A
PRME Prime Medicine	$3.85M	90.47	N/A	N/A	$1.37 per share	1.93

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
GOSS Gossamer Bio	-$56.53M	-$0.23	N/A	N/A	N/A	-41.12%	-128.98%	-15.52%	8/11/2025 (Estimated)
OKYO OKYO Pharma	-$16.83M	N/A	0.00	N/A	N/A	N/A	N/A	N/A	8/12/2025 (Estimated)
OLMA Olema Pharmaceuticals	-$129.47M	-$2.01	N/A	N/A	N/A	N/A	-42.31%	-38.32%	8/5/2025 (Estimated)
PRME Prime Medicine	-$198.13M	-$1.61	N/A	N/A	N/A	N/A	-107.87%	-74.97%	N/A

Latest OKYO, GOSS, PRME, and OLMA Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
5/15/2025	Q1 2025	GOSS Gossamer Bio	-$0.18	-$0.16	+$0.02	-$0.16	$3.95 million	$9.89 million
5/13/2025	Q1 2025	OLMA Olema Pharmaceuticals	-$0.49	-$0.36	+$0.13	-$0.36	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
GOSS Gossamer Bio	N/A	N/A	N/A	N/A	N/A
OKYO OKYO Pharma	N/A	N/A	N/A	N/A	N/A
OLMA Olema Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
PRME Prime Medicine	$1.45	54.57%	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
GOSS Gossamer Bio	6.70	5.71	5.71
OKYO OKYO Pharma	N/A	0.28	N/A
OLMA Olema Pharmaceuticals	N/A	15.22	15.22
PRME Prime Medicine	N/A	6.50	6.50

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
GOSS Gossamer Bio	81.23%
OKYO OKYO Pharma	2.97%
OLMA Olema Pharmaceuticals	91.78%
PRME Prime Medicine	70.37%

Insider Ownership

Company	Insider Ownership
GOSS Gossamer Bio	6.70%
OKYO OKYO Pharma	40.46%
OLMA Olema Pharmaceuticals	16.36%
PRME Prime Medicine	22.93%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
GOSS Gossamer Bio	180	227.30 million	212.07 million	Optionable
OKYO OKYO Pharma	7	33.84 million	20.15 million	Not Optionable
OLMA Olema Pharmaceuticals	70	68.42 million	57.23 million	Optionable
PRME Prime Medicine	234	131.29 million	100.38 million	Optionable

OKYO, GOSS, PRME, and OLMA Headlines

Recent News About These Companies

Prime Medicine, Inc. (NYSE:PRME) Major Shareholder David R. Liu Purchases 21,000 Shares

June 24 at 4:53 AM | insidertrades.com

Insider Buying: Prime Medicine, Inc. (NYSE:PRME) Major Shareholder Purchases 21,000 Shares of Stock

June 23, 2025 | marketbeat.com

Head to Head Survey: Voyager Therapeutics (NASDAQ:VYGR) vs. Prime Medicine (NYSE:PRME)

June 20, 2025 | americanbankingnews.com

Prime Medicine’s Technological Edge and Strategic Positioning Highlighted as Key Investment Opportunity

June 17, 2025 | tipranks.com

Prime Medicine, Inc. (NYSE:PRME) Major Shareholder Acquires $31,290.00 in Stock

June 17, 2025 | insidertrades.com

Insider Buying: Prime Medicine, Inc. (NYSE:PRME) Major Shareholder Acquires 21,000 Shares of Stock

June 16, 2025 | marketbeat.com

Prime Medicine, Inc. (NYSE:PRME) Major Shareholder Acquires $33,600.00 in Stock

June 12, 2025 | marketbeat.com

Two Sigma Investments LP Sells 152,374 Shares of Prime Medicine, Inc. (NYSE:PRME)

June 10, 2025 | marketbeat.com

Prime Medicine, Inc. (NYSE:PRME) Given Consensus Recommendation of "Moderate Buy" by Brokerages

June 4, 2025 | marketbeat.com

Millennium Management LLC Reduces Stake in Prime Medicine, Inc. (NYSE:PRME)

May 30, 2025 | marketbeat.com

Prime Medicine to Participate in Upcoming Investor Conferences

May 29, 2025 | globenewswire.com

Prime Medicine's (PRME) "Neutral" Rating Reaffirmed at Citigroup

May 28, 2025 | marketbeat.com

Citigroup Downgrades Prime Medicine (PRME)

May 28, 2025 | msn.com

Citi Downgrades Prime Medicine (PRME) to Neutral, Cuts PT to $1.50 Due to Market Uncertainty

May 27, 2025 | msn.com

6 Analysts Assess Prime Medicine: What You Need To Know

May 21, 2025 | nasdaq.com

CEO among 25% of staff out the door at cash-strapped Prime

May 20, 2025 | thepharmaletter.comT

Prime Medicine CEO exits as biotech shelves sole clinical gene therapy, lays off 25% of staff

May 20, 2025 | fiercebiotech.comF

Prime Medicine claims ‘proof of concept,’ but lays off staff in pivot

May 20, 2025 | biopharmadive.comB

CRISPR pioneer Prime Medicine switches CEO and lays off quarter of its staff

May 20, 2025 | bostonglobe.comB

Prime Medicine drops after cutting CGD program amid restructuring

May 20, 2025 | msn.com

Prime Medicine stock plummets amid restructuring and leadership changes

May 20, 2025 | msn.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

OKYO, GOSS, PRME, and OLMA Company Descriptions

Gossamer Bio NASDAQ:GOSS

$1.30 -0.06 (-4.41%)

Closing price 06/26/2025 04:00 PM Eastern

Extended Trading

$1.34 +0.04 (+3.46%)

As of 06/26/2025 07:44 PM Eastern

Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary arterial hypertension (PAH) in the United States. The company is developing GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial for the treatment of PAH. It has license agreements with Pulmokine, Inc. to develop and commercialize GB002 and related backup compounds. The company was formerly known as FSG, Bio, Inc. and changed its name to Gossamer Bio, Inc. in 2017. Gossamer Bio, Inc. was incorporated in 2015 and is headquartered in San Diego, California.

OKYO Pharma NASDAQ:OKYO

$2.42 -0.05 (-2.02%)

Closing price 06/26/2025 04:00 PM Eastern

Extended Trading

$2.42 +0.00 (+0.21%)

As of 06/26/2025 07:49 PM Eastern

OKYO Pharma Limited, a clinical-stage biopharmaceutical company, engages in developing therapeutics for patients suffering from inflammatory eye diseases and ocular pain in the United Kingdom. Its lead preclinical product candidate is OK-101, which is in Phase II clinical trials for the treatment of dry eye disease. The company is also developing OK-201, a bovine adrenal medulla, lipidated-peptide preclinical analogue candidate for the treatment of neuropathic chronic pain. The company was incorporated in 2007 and is headquartered in London, the United Kingdom.

Olema Pharmaceuticals NASDAQ:OLMA

$4.56 -0.19 (-4.00%)

Closing price 06/26/2025 04:00 PM Eastern

Extended Trading

$4.47 -0.09 (-1.86%)

As of 04:00 AM Eastern

Olema Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women's cancers. Its lead product candidate is OP-1250, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 3 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer; and OP-1250 combine with CDK4/6 inhibitors palbociclib, ribociclib, and alpelisib in Phase 1/2 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive human epidermal growth factor receptor 2-negative breast cancer, as well as develops OPERA-01 for the of ER+/HER2- advanced or metastatic breast cancer. The company was formerly known as CombiThera, Inc. and changed its name to Olema Pharmaceuticals, Inc. in March 2009. Olema Pharmaceuticals, Inc. was incorporated in 2006 and is headquartered in San Francisco, California.

Prime Medicine NYSE:PRME

$2.65 +0.23 (+9.50%)

Closing price 06/26/2025 04:00 PM Eastern

Extended Trading

$2.65 0.00 (-0.04%)

As of 04:38 AM Eastern

Prime Medicine, Inc., a biotechnology company, delivers genetic therapies to address the spectrum of diseases by deploying gene editing technology. The company offers Prime Editors with a Prime Editor protein, comprising a fusion between a Cas protein and a reverse transcriptase enzyme; and a pegRNA, which targets the Prime Editor to a specific genomic location and provides a template for making the desired edit to the target DNA sequence. It has a research collaboration with Cimeio Therapeutics to develop Prime Edited Shielded-Cell & Immunotherapy Pairs for genetic diseases, acute myeloid leukemia, and myelodysplastic syndrome. The company was incorporated in 2019 and is based in Cambridge, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time